Collaboration - April 10, 2019
The Spring issue of our magazine is out now!
Don’t forget to subscribe to our magazine and read inspiring interviews, in-depth stories and articles about the Nordic life science industry’s progress and challenges. This issue is for example filled with inspiring articles about scientists and business leaders, including the new CEO of AstraZeneca Sweden, Katarina Ageborg, and LEO Pharma’s admired CEO, Gitte Aabo. We […]
Clinical Trials - April 5, 2019
LEO Pharma initiates clinical trial of microarray patches for psoriasis treatment
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients. Microarray patch A microarray patch […]
Collaboration - March 29, 2019
AstraZeneca and Daiichi Sankyo enter collaboration
The global development and commercialization collaboration agreement with Daiichi Sankyo is for trastuzumab deruxtecan (DS-8201), a antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment. Trastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression. In 2017, trastuzumab deruxtecan was granted […]
Collaboration - March 20, 2019
Pilloxa in strategic partnership with Bayer
Swedish Pilloxa is initiating a collaboration with the Scandinavian branch of Bayer and get the opportunity to introduce more people to their smart pillbox through Bayer’s network, both in Scandinavia and globally. “We see great potential in this innovation. For someone not too familiar in the subject it might seem like a trivial task to take […]
Collaboration - February 27, 2019
Orion’s rolling submission to FDA completed
Orion Corporation and Bayer have announced the completion of the rolling submission of a New Drug Application (NDA) for darolutamide to the U.S. Food and Drug Administration (FDA). The submission, which was initiated in December 2018, is based on data from the Phase III ARAMIS trial in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showing […]
Clinical Trials - February 26, 2019
Phase III results from AstraZeneca
AstraZeneca and MSD have announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo. The safety and tolerability profile of Lynparza was consistent with previous trials. POLO is a randomized, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line […]
